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Abstract
Background A body mass index (BMI) adjusted weight loss grading system (WLGS) is related to survival in patients with
cancer. The aim of this study was to examine the applicability of the WLGS by conﬁrming its prognostic validity, evaluating
its relationship to cachexia domains, and exploring its ability to predict cachexia progression.
Methods An international, prospective observational study of patients with incurable cancer was conducted. For each
patient, weight loss grade was scored 0–4. Weight loss grade 0 represents a high BMI with limited weight loss, progressing
through to weight loss grade 4 representing low BMI and a high degree of weight loss. Survival analyses were used to conﬁrm
prognostic validity. Analyses of variance were used to evaluate the relationship between the WLGS and cachexia domains
[anorexia, dietary intake, Karnofsky performance status (KPS), and physical and emotional functioning]. Cox regression was
used to evaluate if the addition of cachexia domains to the WLGS improved prognostic accuracy. Predictive ability of cachexia
progression was assessed by estimating proportion of patients progressing to a more advanced weight loss grade.
Results One thousand four hundred six patients were analysed (median age 66 years; 50% female, 63% KPS ≤ 70). The
overall effect of the WLGS on survival was signiﬁcant as expressed by change in −2 log likelihood (P < 0.001) and persisted
after adjustment for age, sex, and cancer type and stage (P < 0.001). Median survival decreased across the weight loss grades
ranging from 407 days (95% CI 312–502)—weight loss grade 0 to 119 days (95% CI 93–145)—weight loss grade 4. All cachexia
domains signiﬁcantly deteriorated with increasing weight loss grade, and deterioration was greatest for dietary intake, with a
difference corresponding to 0.87 standard deviations between weight loss grades 0 and 4. The addition of KPS, anorexia, and
physical and emotional functioning improved the prognostic accuracy of the WLGS. Likelihood of cachexia progression was
greater in patients with weight loss grade 2 (39%) than that with weight loss grade 0 (19%) or 1 (22%).
Conclusions The WLGS is related to survival, cachexia domains, and the likelihood of progression. Adding certain cachexia
domains to the WLGS improves prognostic accuracy.
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Introduction
Cancer cachexia was ﬁrst described by Hippocrates as severe
weight loss and a sign of impending death.1 It is considered
to be one of the most distressing aspects of advanced cancer,
resulting in progressive functional impairment and
psychological distress,2,3 and it impedes the delivery of
anticancer treatment.4,5 About 80% of patients with advanced
cancer experience weight loss,6 which is a key component of
cancer cachexia. Cachexia contributes to about 20% of
cancer‐related deaths.6,7 Despite this, there has been relatively
little research in this area, resulting in a failure to advance
treatment and a therapeutic nihilism that cachexia is an
inevitable and untreatable consequence of advanced cancer.8
One of the barriers to cachexia research has been the lack
of an agreed deﬁnition and classiﬁcation system. The latter is
fundamental as cancer cachexia is not a single entity but a
syndrome with various stages.9 Various deﬁnitions have been
used, resulting in heterogeneous research populations,
making comparison of ﬁndings difﬁcult.10
A major step in advancing the research agenda in cachexia
was taken in 2011 when a consensus‐based cachexia
deﬁnition was published.11 Cachexia was deﬁned as a
‘multifactorial syndrome characterized by an ongoing muscle
loss (with or without fat loss) that cannot be fully reversed by
nutritional support and leads to progressive functional
impairment’.11 Integral was the idea that cachexia is a
progressive process from an early to a late stage, and the
stages of pre‐cachexia, cachexia, and refractory cachexia
were proposed (Figure 1). Diagnostic criteria, based
predominantly on weight loss and body mass index (BMI),
were assigned to the cachexia stage, whereas for the other
stages, only suggestive characteristics were presented.
Further work was recommended to validate the deﬁnition
and classiﬁcation.
Another important step forward was made when Martin
et al.12 conﬁrmed that severity of weight loss depends on
the concurrent depletion of fat and muscle reserves. They
showed that weight loss, adjusted for concurrent BMI,
predicted survival; patients with a low degree of weight loss
and a high BMI had the best prognosis, and those with a high
degree of weight loss and a low BMI had the worst prognosis.
By combining weight loss and BMI, they produced and
validated a weight loss grading system (WLGS) ranging from
0 to 4, with each weight loss grade predicting survival
independently of cancer type and stage, age, sex, and
performance status.
The WLGS was not intended as a classiﬁcation system of
cancer cachexia. However, because weight loss is a key
component of the syndrome, the WLGS could still potentially
be used to classify cancer cachexia. In order to test this
hypothesis, concurrent validity in relation to established
cachexia domains needs to be demonstrated. Further,
because cachexia is a trajectory from pre‐cachexia to
refractory cachexia, a classiﬁcation system should be able to
predict which patients are at risk of having cachexia
progression. This is of particular interest early in the cachexia
trajectory.
Thus, the present study had three aims: (i) to conﬁrm the
prognostic validity of the WLGS in an independent,
prospective cohort of patients with incurable cancer; (ii) to
evaluate the concurrent validity of the WLGS in relation to
cachexia domains (anorexia, dietary intake, performance
status, and physical and emotional functioning) and to
explore if adding these domains to the WLGS improves
prognostic accuracy; and (iii) to evaluate if the WLGS predicts
cachexia progression.
Methods
Patients and study design
Between April 2011 and October 2013, 1739 patients from 30
centres across Europe (27), Canada (2), and Australia (1) were
included in the European Palliative Care Cancer Symptom
Figure 1 Postulated stages of cachexia (Reprinted from The Lancet Oncology, 12(5), Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL,
et al., Deﬁnition and classiﬁcation of cancer cachexia: an international consensus, 489–95, Copyright (2011), with permission from Elsevier).
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study.13 This was a prospective observational study by the
European Palliative Care Research Centre (PRC) and the
European Association for Palliative Care (EAPC) Research
Network with the aim of improving the understanding of
the development of symptoms and how these symptoms
may best be assessed and classiﬁed in order to improve
symptom management. Eligible patients met the following
key criteria: ≥18 years of age, with incurable cancer, enrolled
in a palliative care programme, and available for at least one
follow‐up registration. All patients provided written informed
consent.
Data collection and weight loss grading
Patients were assessed at baseline and approximately every
4 weeks for at least three follow‐up visits or until death.
The following information was collected: patient
demographics, height, current body weight, and patient‐
reported weight loss in the 6 months prior to inclusion.
Weight loss at subsequent visits was computed by adding
measured weight change to baseline‐reported weight loss.
BMI was recalculated at every visit based on current body
weight. Weight loss grade was assessed and given a score
of 0–4 by combining weight loss and BMI (Table 1).12
Table 2 includes the items from the Patient‐Generated
Subjective Global Assessment (PG‐SGA)14 and the European
Organization for Research and Treatment of Cancer Quality
of Life Questionnaire (EORTC‐QLQ) C15 PAL15 that were used
to collect data pertaining to the cachexia domains for
nutrition and functional and psychosocial effects. Both
instruments are commonly used and well validated patient
reported outcome measurements. The clinical meaning of
PG‐SGA scores is listed in Table 2. Regarding the EORTC‐
QLQ, a difference in score of ≥20 was considered a deﬁnite
clinical signiﬁcant difference, a difference in score of 10–20
was considered a moderate difference, and a difference in
score of 5–10 was considered a small difference.16 In
addition, health care personnel‐reported performance status
(Karnofsky scale) was assessed due to its long standing
importance in cancer prognostication.17 The Karnofsky scale
ranges from 0 (Dead) to 100 (normal, no complaints, and
no evidence of disease).
Statistical considerations
To evaluate the prognostic validity of the WLGS, time to
death or last known date to be alive was calculated and
Kaplan–Meier curves were plotted for each grade. Hazard
Table 2. Cachexia domains assessed
Cachexia domain Factors Reported by Instrument Scale
Nutrition Dietary intake Patient PG‐SGA (food intake
sub‐score)14
0 points: unchanged or more than usual
1 point: normal food but less than normal
amount (or nutrition by vein)
2 points: little solid food
3 points: only liquids or nutritional
supplements
4 points: very little of anything
Appetite loss Patient EORTC QLQ C15 PAL15 0–100a
Functional and
psychosocial
effects
Emotional functioning Patient EORTC QLQ C15 PAL15 0–100a
Physical functioning
Fatigue
Performance status Health care
personnel
Karnofsky scale17 0–100a
Abbreviations: EORTC QLQ, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire; PG‐SGA, Patient‐
Generated Subjective Global Assessment.
aFor emotional functioning, physical functioning, and performance status, 100 is the best score, while for appetite loss and fatigue, 100 is
the worst score.
Table 1. Grading of weight loss (0–4) based on percentage weight loss and current body mass index12
Body mass index (kg/m2)
Weight loss (%) ≥28 25–27.9 22–24.9 20–21.9 <20
<2.5 0 0 1 1 3
2.5–5.9 1 2 2 2 3
6–10.9 2 3 3 3 4
11–14.9 3 3 3 4 4
≥15 3 4 4 4 4
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ratios (HRs) were calculated by using Cox proportional hazard
methods. Adjustments for possible differences in age, sex,
and cancer type (digestive organ cancer, respiratory organ
cancer, breast cancer, cancer of urinary tract and male
genitalia, gynaecological cancer, haematological cancer, and
others) and stage (local, locally advanced, or metastatic/
disseminated) between weight loss grades were made.
Adjustments for differences in performance status between
grades were not performed as a worsening in this parameter
is an expected consequence of cachexia progression.
To investigate the baseline differences between weight
loss grades 0 and 4 in terms of severity of appetite loss,
dietary intake, performance status, fatigue, and physical
and emotional functioning, one‐way analysis of variance
was used. A linear test for trend was applied to conﬁrm if
severity increased with grade. Where normality could not
be assumed, the non‐parametric Kruskal–Wallis test and
Jonckheere–Terpstra test were used instead. To illustrate
the magnitude of change over the entire spectrum of the
WLGS, absolute change in mean values between grade 0
and grade 4 was calculated. To rank which domain had the
greatest relative change, the absolute change in mean values
of each domain was divided by its standard deviation.
To examine if the cachexia domains improved the
prognostic validity of the WLGS, a survival prediction model
was built by using Cox proportional hazard methods. The
general prognostic factors age, sex, and cancer type and stage
were added ﬁrst, and then a forward stepwise (likelihood
ratio) method was used to add the cachexia domains
(appetite loss, dietary intake, performance status, fatigue,
and physical and emotional functioning) and the WLGS.
To assess the likelihood of progression of cachexia during
follow‐up, a longitudinal analysis was performed. Weight loss
grade was assessed at every follow‐up visit and the
proportion of patients progressing to higher grades,
improving to lower grades, or dying after 1, 2, and 3 months
was calculated.
High attrition resulting in missing data was expected
because of patient deterioration. Therefore, a sensitivity
analysis replacing missing values with extreme values was
performed to assess the robustness of the longitudinal
analysis. This signiﬁcantly altered the results (data not
shown), and thus, for patients alive but unable to attend
follow‐up, imputations of likely values for missing data on
body weight were performed by using the iterative
estimation and maximization algorithm with auxiliary
Table 3. Baseline characteristics of the total population and by weight loss grade
Total Weight loss grade
0 1 2 3 4
n 1406 326 325 135 347 273
Median age [years] (IQR) 66 (57–74) 65 (56–73) 65 (56–74) 66 (60–74) 66 (56–74) 67 (58–75)
Sex
Female 705 (50%) 173 (53%) 188 (58%) 61 (46%) 166 (48%) 117 (43%)
Male 700 (50%) 153 (47%) 137 (42%) 74 (54%) 181 (52%) 155 (57%)
KPS
≤70 886 (63%) 175 (54%) 162 (50%) 86 (64%) 241 (70%) 222 (81%)
>70 517 (37%) 149 (46%) 163 (50%) 49 (36%) 105 (30%) 51 (19%)
Principal cancer diagnosis
Cancer of the digestive organs 418 (30%) 71 (22%) 85 (26%) 45 (33%) 112 (32%) 105 (38%)
Cancer of the respiratory organs 282 (20%) 58 (18%) 63 (19%) 36 (27%) 70 (20%) 55 (20%)
Breast cancer 252 (18%) 87 (27%) 83 (26%) 22 (16%) 36 (10%) 24 (9%)
Other cancers 174 (12%) 33 (10%) 32 (10%) 10 (7%) 57 (16%) 42 (15%)
Urinary cancer or cancer of the male genitalia 160 (11%) 43 (13%) 38 (12%) 17 (13%) 40 (12%) 22 (8%)
Gynaecological cancer 82 (6%) 27 (8%) 18 (6%) 3 (2%) 16 (5%) 18 (7%)
Haematological cancer 38 (3%) 7 (2%) 6 (2%) 2 (1%) 16 (5%) 7 (3%)
Stage
Local 61 (4%) 15 (5%) 17 (5%) 4 (3%) 18 (5%) 7 (3%)
Locally advanced 148 (11%) 36 (11%) 27 (8%) 12 (9%) 35 (10%) 38 (14%)
Metastatic 1190 (85%) 273 (84%) 279 (86%) 118 (88%) 293 (85%) 227 (83%)
Median time since diagnosis [months] (IQR) 19 (7–48) 25 (11–58) 23 (9–51) 17 (6–37) 14 (5–38) 14 (5–43)
Current oncologic treatment
No treatment 560 (40%) 100 (31%) 97 (30%) 52 (39%) 171 (49%) 140 (51%)
Chemotherapy 625 (45%) 153 (47%) 179 (55%) 67 (50%) 129 (37%) 97 (36%)
Radiotherapy 74 (5%) 19 (6%) 17 (5%) 11 (8%) 15 (4%) 12 (4%)
Hormonal therapy 141 (10%) 48 (15%) 37 (11%) 9 (7%) 24 (7%) 23 (8%)
Other 83 (6%) 30 (9%) 18 (6%) 6 (4%) 20 (6%) 9 (3%)
Mean weight loss (6 months)[%] (SD) 5.9 (7.5) 0.1 (0.4) 0.4 (1.2) 5.3 (2.2) 8.0 (5.8) 16.9 (6.1)
BMI [kg/m2] (SD) 24 (4.9) 29 (3.7) 24 (3.0) 26 (5.2) 23 (3.9) 20 (2.9)
Abbreviations: BMI, body mass index; IQR, interquartile range; KPS, Karnofsky performance status; SD, standard deviation.
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variables sex, height, body weight, weight loss, and appetite
loss. This was done in order to minimize potential bias that
could arise by simply ignoring missing assessments. A
moderate effect of imputations was observed, with the
largest difference seen in patients with weight loss grade 2,
where it led to a computational increase in risk of cachexia
progression of 9 percentage points compared with the non‐
imputed dataset.
Statistical analyses were performed with IBM SPSS Statistics
for Windows, version 21, IBM Corp, Armonk, NY, USA.
Results
A total of 1406 patients had data available on BMI and weight
loss at baseline; those who did not were excluded (n = 333).
Patient characteristics are shown in Table 3. Median [IQR]
age was 66 [57–74] years, 705 (50%) were female, and most
were outpatients (1136, 81%) and had a KPS ≤70 (886, 63%).
The 333 patients who were excluded were signiﬁcantly older
(median age 70 vs. 66), had a poorer performance status
(KPS ≤ 70, 83% vs. 63%) and a shorter median time since
diagnosis (13 vs. 19 months), and were more likely to be
hospice or nursing home inpatients (25% vs. 6%).
Of the 1406 patients included, 574 (41%) patients
completed 3 months of follow‐up, while 259 (18%) died. A
total of 573 (41%) were lost to follow‐up: 239 (17%), 126
(9%), and 208 (15%) after the ﬁrst, second, and third visits
respectively. Although several patients were lost to follow‐
up after the baseline visit, survival data was still available
for a total of 1327 patients.
Prognostic validity
Survival worsenedwith increasing weight loss grade (Figure 2).
The overall effect of the WLGS on survival was signiﬁcant as
expressed by change in −2 log likelihood (P < 0.001) and
persisted after adjustment for age, sex, and cancer type and
stage (P < 0.001).
Median (95% CI) survival ranged from 407 (312–502) days
in weight loss grade 0 to 119 (93–145) days in weight loss
grade 4 (Table 4). Adjusted HR ranged from 1.2 (P = 0.20) in
weight loss grade 1 to 2.2 (P < 0.001) in weight loss grade 4
(Table 4).
Concurrent validity in relation to other cachexia
domains and impact on prognostic accuracy
There was a worsening of all cachexia domains with
increasing weight loss grade (P < 0.001) (Figure 3). Between
grades 0 and 1, the severity of the cachexia domains was
similar with overlapping conﬁdence intervals.
The magnitude of the differences between grades 0 and 4
was greatest for food intake. The mean score worsened from
0.4 to 1.4 (0.87 SD), followed by appetite loss 18 to 48 (0.86
SD), fatigue 42 to 62 (0.69 SD), physical functioning 72 to 54
(0.64 SD), KPS 71 to 63 (0.46 SD), and emotional functioning
69 to 63 (0.29 SD).
When performance status (P < 0.001), physical functioning
(P < 0.001), emotional functioning (P = 0.004), and appetite
loss (P = 0.005) were added to the WLGS (P < 0.001), the
accuracy of survival prediction improved. Of note was that
the magnitude of improvement due to performance status
(Karnofsky) or physical functioning (EORTC‐QLQ C15 PAL)
depended on which of the two factors were added ﬁrst (data
not shown). This indicates some collinearity between the
two. However, they were both highly signiﬁcant when
present together, indicating some degree of independent
contribution, so both were kept in the model.
Predicting the progression of cachexia
Figure 4 is based on the imputed dataset and presents the
likelihood of surviving patients progressing or improving
according to the WLGS dependent on their baseline weight
loss grade. There was a slightly higher tendency of progression
of cachexia in grade 1 compared with grade 0, while the risk
was considerably higher in grade 2. The tendency towards
improvement declined over the last three grades.
Figure 2 Cumulative survival by weight loss grade.
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After 3 months, the proportions of patients with weight
loss grades 0 to 3 progressing to a more advanced weight loss
grade were 19%, 22%, 39%, and 19%, respectively.
Conversely, those with weight loss grade 1 to 4 improving
to a lower weight loss grade were 5%, 13%, 6%, and 4%,
respectively.
Discussion
The present study has conﬁrmed the prognostic validity of
the WLGS in an independent, prospective cohort of patients
with incurable cancer. Moreover, the WLGS also has
concurrent validity in relation to established cachexia
domains and predicts cachexia progression. It has also been
demonstrated that the addition of cachexia domains to the
WLGS serves to improve its prognostic accuracy.
The present study has several implications for the
management of cancer cachexia. Firstly, the ﬁndings support
the observation made previously by Martin et al.12 that
survival signiﬁcantly worsens with increasing weight loss
grade and are consistent with several other publications
showing that patients with involuntary weight loss have a
poor prognosis.4,18,19 Looking at weight loss grades 1 and 2
individually, survival did worsen compared with that at
weight loss grade 0. However, the difference did not reach
Table 4. Median survival, unadjusted and adjusted HRs, and P‐values by weight loss grade
Weight
loss grade na
Number of
deaths
Median survival
[days] (95% CI)
Unadjusted HR
(95% CI) P
Adjusted HR
(95% CI)b P
0 312 156 407 (312–502) 1.0 1.0
1 313 164 301 (244–358) 1.2 (1.0–1.5) 0.11 1.2 (0.9–1.4) 0.20
2 128 78 247 (154–340) 1.5 (1.1–1.9) 0.004 1.3 (1.0–1.7) 0.08
3 328 233 161 (137–185) 2.0 (1.6–2.5) <0.001 1.9 (1.5–2.3) <0.001
4 246 186 119 (93–145) 2.6 (2.1–3.2) <0.001 2.2 (1.8–2.8) <0.001
Abbreviations: CI, conﬁdence interval; HR, hazard ratio.
aFive patients were excluded from the adjusted analysis because of missing values of independent variables.
bAdjusted for age, sex, and cancer type and stage.
Figure 3 Relationship between the different cachexia domains and weight loss grade (error bars: 95% conﬁdence intervals). Analysis of variance and
test for linear trend were signiﬁcant for all cachexia domains (P < 0.001); this was conﬁrmed by non‐parametric analouges (Kruskal–Wallis test and
Jonckheere–Terpstra test) in physical functioning, fatigue, emotional functioning, appetite loss, and dietary intake due to the non‐normal distributions
of these variables.
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statistical signiﬁcance, although weight loss grade 2 showed a
tendency towards signiﬁcance. Failure to reach signiﬁcance
may be due to the smaller sample in the present study
compared with the study by Martin et al.12
Secondly, the WLGS not only predicts survival but the
present ﬁndings suggest that it may also be useful in cachexia
classiﬁcation as it has concurrent validity in relation to
established cachexia domains. Of these, dietary intake and
appetite loss were the factors most strongly related to
increasing grade, which is not surprising given that these
factors are central in the pathophysiology of cancer
cachexia.20 From grades 0 to 4, dietary intake changed from
a mean value of 0.4, representing a near normal intake of
nutrients (normal intake is score 0), to 1.4, which represents
a reduced intake of normal food (or feeding by nasogastric
tube or vein) (score 1) or intake of little solid food (score
2).14 KPS changed from a mean value close to 70 to close to
60, the difference being the ability to fully care for oneself
vs. requiring occasional assistance.17 Appetite loss and
fatigue changed by a score of 20, which is considered to be
a deﬁnite clinical signiﬁcant change. Physical functioning
changed by a score of 18, which is considered to be a
moderate change, and emotional functioning changed by a
score of 6, which is considered to be a small change.16
Performance status, appetite loss, and physical and
emotional functioning improve prognostication of survival
independently of the WLGS. This suggests that they can be
used in combination with the WLGS to further improve the
prognostic ability of the system. Future research should
examine their full potential to classify cancer cachexia.
The third and, arguably, the ﬁnding with the greatest
potential clinical relevance was that weight loss grade was
predictive of the likelihood of cachexia progression. The risk
of progression was considerably higher in weight loss grade
2 compared with that in weight loss grade 0 or 1. This
suggests that more patients have started on the cachexia
trajectory in weight loss grade 2 than in weight loss grade 0
or 1. Notably, the percentage of patients receiving
chemotherapy was similar in patients with weight loss grades
0–2 (47%, 55%, and 50%, respectively), so less anti‐cancer
treatment does not seem to explain the increased risk of
cachexia progression in weight loss grade 2. Regarding the
two most severe grades of the WLGS (grades 3 and 4), the
probability of improvement decreased, reﬂecting that
irreversibility increases as cachexia becomes more advanced.
This is consistent with the ﬁndings of Prado et al. who found
that weight gain is unlikely to occur in the last 90 days of
advanced cancer patients’ lives.21 Overall, the risk of
progression to more severe grades superseded the rate of
improvement at any grade (with the obvious exception of
grade 4), conﬁrming the progressive nature of cachexia.
So how might these ﬁndings inﬂuence practice? One such
way is the early identiﬁcation of patients where cachexia
interventions should be implemented. As less than a quarter
of patients with grades 0 and 1 have cachexia progression, it
would seem sensible to start cachexia intervention for
patients with grade 2 where the likelihood of progression is
greater. That way, one might avoid over‐treating many
patients. This strategy is supported by the ﬁnding that
patients with grade 2 have a higher symptom load (appetite
loss and fatigue), lower dietary intake, and poorer function
than patients with lower weight loss grade. Thus, grade 2
seems to ﬁt the description of pre‐cachexia in the consensus
deﬁnition.11 At the other end of the scale, patients with
grade 4 had a median survival of a little over 3 months and
a mean KPS close to 60. This is in accordance with the
Figure 4 Bar charts for each baseline weight loss grade (0–4) showing the likelihood of improvement to preceding or progress to subsequent grades or
death at 1, 2, and 3 months of follow‐up.
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description of refractory cachexia in the consensus deﬁnition,
and aggressive treatment attempts against cachexia, as well
as chemotherapy, should be avoided in this group of
patients.11 Instead, the attention should be given to palliation
and immediate symptom relief.
The main limitation of this study was the expected, but
considerable, attrition that may have affected the
longitudinal analyses. Presumably, the high dropout rate
was caused by patients deteriorating and becoming too weak
to continue participation. This was addressed by performing
imputations of missing values aiming to reduce the risk of
bias. Another limitation was the lack of information on
important cachexia domains such as systemic inﬂammation
and objective measures of muscle and fat mass. Systemic
inﬂammation is interesting because it is considered a driver
of cancer cachexia,6 and markers of inﬂammation could
potentially be important in diagnosing cachexia. Measures
of muscle and fat mass could have explained whether
observed weight gain was due to improvement of cachexia
or due to accumulation of ﬂuids or shifts in body
composition. Nevertheless, concurrent validity could be
evaluated with regard to important cachexia domains such
as appetite, food intake, and physical function.
Furthermore, because cachexia development is likely to be
affected by the response to chemotherapy, nutrition, and
other treatments of cachexia, one cannot claim that this
study describes the natural development of cachexia in an
untreated population. Nevertheless, it describes the
development of cachexia in a population without systematic
intervention against cachexia. The strengths of this study
are the longitudinal design and the large number of patients
included from several countries, both rare in palliative
research.
Conclusion
Our ﬁndings support that the WLGS predicts survival and is
in keeping with the cancer cachexia phenotype.
Furthermore, the addition of key cachexia domains improves
prognostic accuracy of the WLGS. Prospective clinical trials
should examine the WLGS’s ability to stratify cachexia
treatments. This could have signiﬁcant implications for
clinical practice and challenge the widely accepted paradigm
that cancer cachexia is an inevitable consequence of
advanced disease.
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